Guest Contributor

GlaxoSmithKline's Canadian operations possess formidable R&D strengths that could increase in wake of recent merger

Guest Contributor
January 29, 2001

The Canadian arm of the newly merged GlaxoSmithKline plc is hoping that the combination of the two companies will create a powerful lure for attracting new corporate funding into its growing R&D operations and expanding partnerships with universities, the biotechnology sector and the Canadian Institutes of Health Research (CIHR).

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics

Other News

RE$EARCH MONEY Analysis: Science and technology proposals and requests for additional funding left hanging in absence of normal Budget cycle

Determining the centre of decision-making power for science and technology initiatives spurs growing debate in Ottawa

NSERC introduces dramatic new measures to increase flexibility and improve linkages to innovation

MEDICAL BRIEFS






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.